We recently compared the regulation of glucose-6-phosphatase (G6Pase) catalytic subunit and glucose-6-phosphate (G6P) transporter gene expression by insulin in conscious dogs in vivo (Hornbuckle et al. Am. J. Physiol. Endocrinol. Metab. 281:E713-725, 2001). In pancreatic-clamped, euglycemic conscious dogs, a 5 hr period of hypoinsulinemia led to a marked increase in hepatic G6Pase catalytic subunit mRNA; however, G6P transporter mRNA was unchanged. Here we demonstrate, again using pancreatic-clamped, conscious dogs, that glucagon is a candidate for the factor responsible for this selective induction. Thus, glucagon stimulated G6Pase catalytic subunit but not G6P transporter gene expression in vivo. Furthermore, cAMP stimulated endogenous G6Pase catalytic subunit gene expression in HepG2 cells but had no effect on G6P transporter gene expression. The cAMP response element (CRE) that mediates this induction was identified through transient transfection of HepG2 cells with G6Pase catalytic subunit-chloramphenicol acetyltransferase (CAT) fusion genes. Gel retardation assays demonstrate that this CRE binds several transcription factors including CREB and C/EBP.
Introduction
During fasting conditions, the liver supplies the body with glucose through the breakdown of glycogen stores and through de novo synthesis from gluconeogenic precursors. Glucose-6-phosphatase (G6Pase) catalyzes the final step in both of these pathways, hydrolyzing glucose-6-phosphate (G6P) to glucose and inorganic phosphate. In 1975 Arion et al. (6) proposed that G6Pase exists as an enzyme system of multiple components, each embedded in the endoplasmic reticulum (ER) membrane. According to this so-called substrate-transport model, G6P translocates across the membrane via a specific transporter.
Once in the lumen, G6P is then hydrolyzed by the system's catalytic subunit, a relatively non-specific phosphatase. Glucose and inorganic phosphate transporters then shuttle the reaction products, glucose and inorganic phosphate, to the cytoplasm. While no model of the G6Pase system appears to account fully for all the reported kinetic data (22, 55, 76, 77) , the validity of the substrate-transport model has been supported by the identification of a G6P transporter located in the ER membrane (26, 42) .
Pathophysiologic conditions arising from aberrant activity of either the G6Pase catalytic subunit or the G6P transporter have demonstrated the importance of the G6Pase system. Inactivating mutations in the G6Pase catalytic subunit or G6P transporter result in glycogen storage disease (GSD) types 1a and 1b, respectively; patients with such mutations suffer from severe hypoglycemia in the postabsorbtive state, among other defects (12) . Conversely, increased expression of both the G6Pase catalytic subunit and G6P transporter may contribute to the elevated hepatic glucose production (HGP) characteristic of both poorly controlled type 1 and type 2 diabetes. In the liver of diabetic animal models, mRNA levels of both genes are markedly elevated (4, 29, 40, 44, 50, 56) . Furthermore, adenoviral overexpression of either gene in hepatocytes results in enhanced rates of G6P hydrolysis and altered glycogen metabolism (1, 70) .
We have been interested in investigating whether the expression of the genes encoding the G6Pase catalytic subunit and the G6P transporter are regulated in parallel in the liver, or whether hormones and nutrients differentially regulate their expression. We first addressed this question by examining the effects of insulin and glucose on the expression of these genes in vivo in the liver of conscious dogs. In hyperinsulinemic dogs, the expression of both the G6Pase catalytic subunit and G6P transporter genes was suppressed (35) . This suppression of the expression of both genes by insulin was also apparent in the liver-derived H4IIE cell line (35) . In contrast, in hypoinsulinemic dogs, G6Pase catalytic subunit mRNA levels were four-fold greater than those of control dogs whereas G6P transporter gene expression was unchanged (35) . This result indicates that insulin tonically suppresses hepatic G6Pase catalytic subunit but not G6P transporter gene expression in vivo (35) .
Unfortunately, tissue culture studies cannot directly address the question as to what factor, or factors, mediate the selective elevation of G6Pase catalytic subunit gene expression in the absence of insulin in vivo. Nevertheless, the observation that cAMP selectively stimulated G6Pase catalytic subunit gene expression in primary hepatocytes and in H4IIE hepatoma cells suggested that glucagon may contribute to the differential regulation observed in vivo (35) . However, fatty acids and glycerol were also candidates to explain this differential regulation because insulin inhibits lipolysis and therefore the hypoinsulinemia induced in these studies also resulted in an increase in the levels of both non-esterified fatty acids (NEFAs) and glycerol (18) . Although the effects of fatty acids and glycerol on G6P transporter gene expression have not been reported, both these agents regulate G6Pase catalytic subunit gene expression. Thus, infusion of conscious rats with triglycerides (51) or treatment of primary hepatocytes with long chain fatty acids (11) both elevate G6Pase catalytic subunit mRNA. Additionally, at low concentrations, the gluconeogenic substrate glycerol increases G6Pase catalytic subunit mRNA levels in primary hepatocytes (48) .
The studies presented here were designed to address the question as to what factor, or factors, are candidates to mediate the selective elevation of G6Pase catalytic subunit gene expression in the absence of insulin in vivo. This was achieved by using the metabolically-clamped conscious dog model to assess the effects of glucagon, fatty acids and glycerol on hepatic G6Pase catalytic subunit and G6P transporter gene expression.
Methods

Materials.
[α- 32 respectively. Human genomic DNA was purchased from Promega. Antisera raised against various C/EBP isoforms were generously provided by Dr. Steven L. McKnight (8) . Antiserum raised against CREB was purchased from NEB/Cell Signaling Technology (Cat. #9192).
Animal Care. Experiments were conducted on fourteen 18 h fasted conscious mongrel dogs (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) the hepatic portal vein, and left femoral artery as previously described (16) . All catheters were filled with heparinized saline (200 U/ml; Abbott Laboratories, North Chicago, IL) and their free ends were knotted prior to closure of the skin. The catheters were placed in a subcutaneous pocket prior to closure of the abdominal skin.
On the day of the experiment, the catheters were externalized under local anesthesia (2% lidocaine;
Abbott Laboratories, North Chicago, IL). The contents of each catheter were aspirated and the catheters were flushed with saline. The intraportal catheters (splenic and jejunal) were used for the infusion of glucagon and insulin. Angiocaths were inserted percutaneously into peripherial veins for the infusion of µCi/min) was begun to allow the assessment of hepatic glucose production (HGP). Constant infusions of indocyanine green (0.077 mg/min), to assess hepatic blood flow, and somatostatin (0.8 µg/kg/min), to inhibit endogenous insulin and glucagon secretion were also started at -140 min. [3-3 H] glucose, indocyanine green, and somatostatin were given via a leg vein. A constant intraportal infusion of glucagon (0.55 ng/kg/min) was given (t = -140 min) to replace basal endogenous glucagon secretion. Endogenous insulin was replaced at a variable intraportal infusion rate from -140 min to -40 min. The plasma glucose level was monitored every 5 min, and euglycemia was maintained by adjusting the rate of insulin infusion.
Once the plasma glucose level had been stabilized at euglycemia for 30 min, basal sampling began and the infusion rate of insulin remain unchanged thereafter.
The study included four protocols:
Protocol 1 (Hyperglycemia; HG; n = 3): A hyperglycemic clamp was performed. At 15 min, 20%
dextrose was infused via a leg vein to clamp the arterial glucose levels at the levels seen in the groups receiving three times basal glucagon.
Protocol 2 (Hyperglycemia, elevated glucagon; HG + GGN; n = 4): At 15 min, the intraportal glucagon infusion was increased from 0.55 ng/kg/min to three times the basal rate (1.65 ng/kg/min). dextrose was infused via a leg vein to clamp the arterial glucose levels at the increasing levels seen in the groups receiving three times basal glucagon.
Protocol 3 (Hyperglycemia
Protocol 4 (Hyperglycemia, elevated glucagon, elevated fatty acids and glycerol; HG + GGN + NEFA; n = 4): A constant Intralipid (0.02 ml/kg/min) plus heparin (0.5 U/kg/min) infusion was started at 0 min via a leg vein. After a NEFA/glycerol equilibration period (15 min), the intraportal glucagon infusion was increased from 0.55 ng/kg/min to 1.65 ng/kg/min as seen in protocol 2.
The glucagon infusion rate was increased by 7% every hour to correct for glucagon degradation in the groups receiving three times basal glucagon. Arterial blood samples were taken every 10 min during the control period and every 15 min during the experimental period. In the NEFA + HG and HG groups, arterial blood samples were also taken every 5 minutes in order to monitor glucose levels. The total blood volume withdrawn did not exceed 20% of the dog's total blood volume. No significant decrease in hematocrit was observed with this procedure.
Immediately following the final blood sample, each animal was anesthetized with pentobarbital sodium. The animal was then removed from the harness while the hormones, Intralipid/heparin, and/or glucose continued to be infused. A midline laporotomy incision was made, and clamps cooled in liquid nitrogen were used to freeze sections of hepatic lobes two, three, and seven in situ. The hepatic tissue was then cut free, placed in liquid nitrogen, and stored at -70°C. Approximately 2 min elapsed between the time of anesthesia and the time of tissue clamping. All animals were then euthanized.
Animal Sample Collecting, Processing and Analysis. Immediately after each blood sample was drawn, the blood was centrifuged to obtain plasma. Four 10-µl aliquots of plasma were immediately analyzed for glucose by the glucose oxidase method with a Beckman glucose analyzer (Beckman Instruments, Fullerton, CA). A 1-ml aliquot of whole blood was lysed with 3 ml of 4% perchloric acid. The solution was centrifuged, and the supernatant was stored for the future analysis of whole-blood glycerol. A second 1-ml aliquot of whole blood was treated with 20 µl of an antioxidant (glutathione) and centrifuged. This supernatant was then stored for the future determination of catacholamines, epinephrine and norepinephrine. A 1-ml aliquot of plasma received 50 µl of 100,000 kallikrein inhibitor units/ml, Trasylol (FBA Pharmaceuticals, New York, NY), and was stored for analysis of immunoreactive glucagon. The remainder of the plasma was used for analysis of insulin and NEFA. All samples were kept in an ice bath during the experiment and were then stored at 70°C until the assays were performed. Whole blood glycerol concentrations were determined according to the enzymatic methods of Lloyd et al. (45) for the Technicon Autoanalyzer (Tarrytown, NY) and were modified for the Monarch 2000 centrifugal analyzer (Lexington, MA). The levels of epinephrine and norepinephrine were assessed using high performance liquid chromatography as previously described (57) . Immunoreactive insulin was measured using a double-antibody radioimmunoassay (59) . Immunoreactive glucagon was measured using a modification of the double-antibody insulin method (59) . Plasma non-esterified fatty acids were determined spectrophotometrically using the Monarch 2000 centrifugal analyzer and a kit obtained from Wako Chemicals (Richmond, VA).
As the total blood flow entering the liver comes from two sources, 20% from the hepatic artery and 80% from the portal vein, the hepatic sinsusoidal concentration of a substance can be calculated as the arterial concentration multiplied by 0.2 plus the portal concentration multiplied by 0.8,
Cell culture. Human HepG2 hepatoma cells were grown in Dulbecco's modified Eagle's medium containing 2.5% (vol/vol) newborn calf serum, 2.5% (vol/vol) fetal calf serum and 5% (vol/vol) Nu serum IV (Collaborative Research, Inc.) as previously described (61, 74) . The sequence of the human G6P transporter fragment was identical to that previously reported (26) . The plasmid was linearized with Hind III such that in vitro transcription using T7 polymerase generated a 254 nucleotide antisense RNA probe.
The generation of plasmids containing genomic DNA fragments of the dog genes encoding the G6P transporter, the G6Pase catalytic subunit and cyclophilin A has been previously described (35) . These plasmids were linearized with Hind III or Sac I, as previously described (35) , such that in vitro transcription using T7 polymerase generated 254, 335 or 121 nucleotide antisense RNA probes, respectively. A linearized plasmid containing a fragment of the human cyclophilin A gene was purchased from Ambion Inc. and was used to generate a 165 nucleotide antisense probe.
Ribonuclease protection assay (RPA).
[α-32 P]UTP labeled antisense dog G6P transporter, G6Pase catalytic subunit and cyclophilin A probes as well as human G6P transporter and cyclophilin A probes were generated using the linearized plasmids described above and the MAXIscript T7 kit (Ambion) according to the manufacturer's instructions. Ribonuclease protection assays were performed using 10 µg of total dog liver or HepG2 RNA and the RPA III kit (Ambion), again according to the manufacturer's instructions, except that the combined RNA and probe precipitate was dissolved in 1µl water prior to the addition of 10 µl hybridization buffer. Following RNase A/T1 digestion RNA products were resolved on 5% polyacrylamide/urea/TBE gels and sizes estimated by comparison with co-electrophoresed DNA sequencing reactions. The sizes of the human G6P transporter and human cyclophilin A products were close to the calculated sizes of 201 and 103 nucleotides, respectively. The human G6P transporter product appeared as a doublet ( RNA for 1 hr at 60˚C, and then primer extension was performed as previously described (21) . Extension products were visualized by electrophoresis on polyacrylamide/urea/TBE gels (21) . The sizes of the extension products were calculated by comparison with a DNA sequencing ladder. The human G6Pase catalytic subunit primer gave the predicted extension product of 168 nucleotides (39) . With HepG2 RNA the cyclophilin A primer gave a cluster of extension products between 73 and 75 nucleotides ( CRE1 SDM and -231 CRE2 SDM) have all been previously described (47, 72, 75) .
The generation of the heterologous XMB vector that contains a minimal Xenopus 68 kDa albumin promoter ligated to the CAT reporter gene has previously been described (10) HinD III compatible end underlined; CRE core in italics) and a consensus CRE (Sense:
GATCAGATTGCCTGACGTCAAGAGCT; BamH I compatible end underlined; CRE core in italics) were synthesized and subsequently gel purified, annealed, and labeled with [α-32 P]dATP using the Klenow fragment of Escherichia coli DNA Polymerase I to a specific activity of approximately 2.5 µCi/pmol (66).
The labeled double-stranded oligonucleotide probes (~7 fmol, ~50,000 cpm) were incubated with HepG2 nuclear extract (8 µg) in a final reaction volume of 20 µl containing 20 mM HEPES (pH 7.9), 100 mM NaCl, 0.06 mM spermidine, 0.01 mM spermine, 0.5 mM EDTA, 0.5 mM EGTA, 1 mM DTT, 12.5% glycerol (vol/vol), 0.5 µg of poly(dI-dC)•poly(dI-dC) and 0.5 µg of poly(dA-dT)•poly(dA-dT). After incubation for 20 minutes at room temperature, the reactants were loaded onto a 6% polyacrylamide gel and electrophoresed for 90 min at 150 V at room temperature in a buffer containing 25 mM Tris at pH 7.8, 190
mM glycine and 1 mM EDTA. Following electrophoresis the gels were dried, exposed to Kodak XAR5 film, and binding was analyzed by autoradiography.
For competition experiments a 100-fold molar excess of various unlabeled double-stranded oligonucleotides ( Fig. 8) were incubated with the labeled oligomer prior to the addition of HepG2 nuclear extract. Gel supershift assays were carried out by incubating HepG2 nuclear extract with the indicated antisera (1 µl) for 10 minutes on ice, prior to the addition of the labeled oligonucleotide probe and binding buffer and incubation for an additional 20 min at room temperature. Binding was then analyzed by polyacrylamide gel electrophoresis as described above.
Statistical analysis. The animal study data were analyzed for differences between basal period and experimental period values using a paired Student t-test and for differences from the control group values using an unpaired Student t-test. The RNA study and transfection data were analyzed for differences from the control group values using an unpaired Student t-test. The level of significance was P < 0.05 (twosided test).
Results
Metabolic parameters of in vivo conscious dog studies. Four protocols were utilized in which glucagon, free fatty acids, and glycerol were selectively manipulated in conscious dogs in vivo (Fig. 1) . This was achieved, following an 18-hour fast, by the continuous administration of somatostatin throughout the study so as to block endogenous pancreatic hormone secretion. In all four protocols hyperglycemia was achieved during the experimental period either directly through glucose infusion or as a consequence of elevated glucagon levels (Fig. 1) . We have previously shown that the level of hyperglycemia achieved (~200 mg/dL) has no effect on G6Pase catalytic subunit or G6P transporter gene expression in conscious dogs in vivo (35) . Insulin was infused at a rate sufficient to achieve euglycemia during the basal period; this insulin infusion rate was maintained during the experimental period. This strategy was designed to offset variations in insulin sensitivity between animals and so ensure a similar degree of insulin signaling in each animal. Thus, the actual basal insulin concentration required to achieve euglycemia varied modestly between animals. Glucagon was supplied at either basal rates during the basal and experimental periods, with glucose then clamped at a hyperglycemic level during the experimental period, or it was supplied at approximately three-fold the basal rate during the experimental period, in which case glucose was permitted to respond to the change in glucagon concentration (Fig. 1) . The study was designed such that the level of hyperglycemia achieved was similar in each case. Finally, infusions of the triglyceride emulsion Intralipid allowed manipulation of both fatty acid and glycerol concentrations to a level approximately 3-fold above basal. The actual changes in sinusoidal plasma glucose, insulin, glucagon, NEFA, and glycerol levels in the four experimental groups during the transition between the basal and experimental periods are described in the legend to Figure 1 . The mean levels ± S.E.M. during the final two hours of the experimental period are shown in Figure 2 . The data in Figure 2 show that these experimental manipulations achieved the desired goals. Thus, glucose ( Fig. 2A) and insulin ( Fig. 2B ) levels were statistically no different between the four groups of animals whereas glucagon levels were selectively increased in protocols 2 and 4 ( Fig. 2C) .
Similarly, glycerol (Fig. 2D ) and NEFA levels ( Fig. 2E) were selectively increased in protocols 3 and 4.
Selective regulation of G6Pase catalytic subunit and G6P transporter gene expression in vivo.
Freezeclamped liver samples were removed from anesthetized dogs immediately following the experimental period. Total RNA was then isolated and ribonuclease protection assays (RPAs) were performed to quantify G6Pase catalytic subunit, G6P transporter and cyclophilin A mRNA levels. RPA probes representing fragments of the dog G6Pase catalytic subunit, G6P transporter and cyclophilin A genes were all generated using PCR in conjunction with primers representing conserved sequences in the mouse, rat and human genes. Expression of the latter is not responsive to hormones/metabolites such that it serves as an internal control. Therefore, the effects of glucagon, fatty acids/glycerol on G6Pase catalytic subunit and G6P transporter mRNA levels are quantitated relative to the level of cyclophilin A mRNA in the same samples.
As shown in Figure 3 , when glucagon levels were elevated above basal and glucose levels were allowed to rise in response (Protocol 2), G6Pase catalytic subunit mRNA levels increased ~2.5-fold over those assayed in hyperglycemic animals (Protocol 1) (p<0.05). In contrast, G6P transporter gene expression was not significantly changed (Fig. 3 ). This stimulation of G6Pase catalytic subunit gene expression cannot be due to the secondary rise in glucose levels induced by the elevation in glucagon concentration since the glucose level achieved was identical to that in hyperglycemic animals (Fig. 2) . In contrast to the effect of glucagon, infusion of Intralipid failed to stimulate an increase in either G6Pase catalytic subunit or G6P transporter gene expression (Fig. 3) . Moreover, the magnitude of the stimulatory effect of glucagon on G6Pase catalytic subunit gene expression in combination with Intralipid was no different to that seen in the presence of glucagon alone (Fig. 3) .
G6Pase catalytic subunit and G6P transporter mRNA levels do not vary with location within the liver.
The canine liver can be functionally divided into seven lobes according to the relative contributions of the hepatic artery and portal vein to the blood supply (19) . However, the data shown in Figure 3 was obtained using RNA isolated from only hepatic lobe 7 of each dog. Therefore, we were concerned about the theoretical possibility that the basal and/or hormone-regulated expression of the G6Pase catalytic subunit and G6P transporter genes might vary between different liver lobes. Indeed, the expression levels of some genes, such as c-fos, do vary between lobes (33) although others, such as collagen, do not (25) . We therefore compared the relative expression level of these genes in liver lobes 2, 3 and 7 in eight individual metabolically-clamped dogs. Four of these dogs had been subject to hyperglycemia (28) and four had been subject to hyperglycemia plus elevated glucagon (Protocol 2; Fig. 1 ). There were no significant differences in the expression level of either gene among the three lobes examined, regardless of the experimental conditions (data not shown). This suggests that the results shown in Figure 3 are representative of G6Pase catalytic subunit and G6P transporter mRNA levels throughout the liver.
Glucagon stimulates G6Pase catalytic subunit fusion gene expression in HepG2 hepatoma cells.
The results from the in vivo dog liver studies described above suggest that elevation of glucagon levels can selectively induce G6Pase catalytic subunit gene expression. This stimulation of G6Pase catalytic subunit gene expression by glucagon in vivo cannot be due to the secondary rise in glucose levels induced by the elevation in glucagon concentration since the glucose level achieved was identical to that in the control, hyperglycemic animals (Fig. 2) . However, this experiment cannot formally rule out the possibility that glucagon alters the abundance of another metabolite/factor that then mediates the induction of G6Pase catalytic subunit gene expression.
To address this caveat, a G6Pase catalytic subunit-luciferase fusion gene, containing G6Pase catalytic subunit promoter sequence from -231 to +66, relative to the transcription start site at +1 (47, 72) , was transiently transfected into HepG2 cells and the effect of glucagon on fusion gene expression was assessed (Fig. 4) . Although it has been reported that HepG2 cells respond to glucagon treatment (71) most studies suggest that glucagon receptors are markedly downregulated in hepatoma cells (20, 54) . Not surprisingly, therefore, glucagon failed to induce G6Pase catalytic subunit-luciferase fusion gene expression in HepG2 cells (Fig. 4A) . However, glucagon did stimulate reporter gene expression when the G6Pase catalytic subunit-luciferase fusion gene was co-transfected with an expression vector encoding the glucagon receptor (Fig. 4A ). In the absence of glucagon, co-transfection with the glucagon receptor alone had little effect on G6Pase catalytic subunit-luciferase fusion gene expression, suggesting a low level of signaling through the basal receptor (Fig. 4B) . The maximal effect of glucagon on G6Pase catalytic subunit-luciferase gene expression was seen at ~100 nM (Fig. 4C) Since HepG2 cells are transfected with a low efficiency it was not possible to look at the effect of glucagon on endogenous G6Pase catalytic subunit gene expression. Therefore, we treated cells with the cAMP analogue 8-CPT cAMP for three hours, following overnight serum starvation, and then harvested total RNA. Primer extension analyses and ribonuclease protection assays were used to quantify G6Pase catalytic subunit and G6P transporter mRNA levels, respectively, and expression of the cyclophilin A gene was again used as an internal control. As shown in Figure 5 Thus glucocorticoids induce expression of the endogenous hepatic G6Pase catalytic subunit gene (24) but the synthetic glucocorticoid analogue dexamethasone did not significantly stimulate expression of this gene, or the G6P transporter gene, in HepG2 cells (Fig. 5) . We have previously shown that dexamethasone stimulates the expression of both genes in H4IIE rat hepatoma cells (35) suggesting that these cells are a better model, at least with respect to glucocorticoid signaling. We have previously shown that, in HepG2 cells, co-transfection with a plasmid encoding the catalytic subunit of protein kinase A (PKA) more robustly stimulates G6Pase catalytic subunit-CAT fusion gene expression than treatment with a cAMP analog (~15-fold vs 2-3 fold) (75) . Using this approach we demonstrated that multiple promoter elements are required for the stimulatory effect of PKA on G6Pase catalytic subunit-CAT fusion gene expression (75) , rather than the single elements described by other investigators (43, 68) . One of these elements, located between -114 and -99 was subsequently identified as an HNF-6 binding site (73) , however, the results also showed that deletion of the regions encompassing either CRE1 or CRE2 both resulted in a reduction in the maximal effect of PKA on fusion gene expression (75) .
Analysis of cyclic AMP response elements in the mouse
To explore the role of CRE1 and CRE2 in the stimulatory effect of PKA on mouse G6Pase catalytic subunit gene transcription in HepG2 cells, we separately mutated CRE1 and CRE2 in the context of the -231 to +66 G6Pase catalytic subunit-CAT fusion gene. Figure 6A shows that, when the results are expressed in terms of maximal induction of expression by PKA, mutation of both CRE1 and CRE2 results in a decrease in the ability of PKA to stimulate G6Pase catalytic subunit-CAT fusion gene expression in comparison to the wild-type -231 G6Pase catalytic subunit-CAT fusion gene. However, the interpretation of this experiment is complex because mutation of CRE1 and CRE2 also results in a reduction in basal G6Pase catalytic subunit-CAT fusion gene expression (Fig. 6B) . Nevertheless, Figure 6C shows that, even when the results are expressed in terms of fold induction of expression by PKA, mutation of both CRE1
and CRE2 decreases the ability of PKA to stimulate G6Pase catalytic subunit-CAT fusion gene expression.
These data suggest that both sites are required for the stimulation of G6Pase catalytic subunit-CAT fusion gene expression by PKA in HepG2 cells. However, this experiment does not reveal whether CRE1 and CRE2 are acting directly as bona fide CREs or indirectly as accessory factor binding sites to enhance the effect of cAMP mediated through another element.
CRE1, but not CRE2, acts as a bona fide CRE in HepG2 cells. Multiple copies of double stranded
oligonucleotides representing either the mouse G6Pase catalytic subunit sequence from -175 to -142 (CRE1) or from -155 to -119 (CRE2) were ligated into the heterologous XMB-CAT expression vector and transiently transfected into HepG2 cells (Fig. 7) . The G6Pase catalytic subunit promoter sequence from -175 to -142 (CRE1) mediated a direct stimulatory effect of PKA on reporter gene expression ( Fig.   7) , whereas, the sequence from -155 to -119 was unable to mediate a PKA response (Fig. 7) . As a control, a double stranded oligonucleotide containing a mutation of the CRE-like motif within the CRE1 sequence, the same mutation as present in the -231 CRE1 SDM fusion gene (Fig. 6 ), was inserted in multiple copies into the heterologous XMB-CAT expression vector. CAT expression directed by the resulting construct (CRE1 MUT XMB) was not stimulated by PKA following transient transfection into HepG2 cells (Fig. 7) .
These data indicate that the CRE1 region, but not the CRE2 region, contains a bona fide CRE and that the CRE-like motif within CRE1 is responsible for the stimulatory effect of PKA on G6Pase catalytic subunit gene expression. In addition, this result suggests that the CRE2 region contains an accessory factor binding site that likely enhances both basal G6Pase catalytic subunit gene expression (Fig. 6C ) and the effect of cAMP mediated through CRE1.
CREB and C/EBP bind the G6Pase catalytic subunit CRE. When a labeled oligonucleotide representing
the wild-type (WT) G6Pase catalytic subunit promoter sequence from -175 to -142 that encompasses CRE1 was incubated with nuclear extract prepared from HepG2 cells several protein-DNA complexes were detected in gel retardation assays (Fig. 8A) . Competition experiments, in which a 100-fold molar excess of unlabeled DNA was included with the labeled probe, were used to correlate protein binding with cAMPregulated G6Pase catalytic subunit gene expression. The wild type CRE1 oligonucleotide competed effectively for the formation of four protein-DNA complexes (Fig. 8A, see arrows) . By contrast, an oligonucleotide, designated CRE1 MUT (75) , that contains a mutation identical to that described in the -231 CRE1 SDM construct (Fig. 6 ), failed to compete with the labeled probe for formation of these complexes (Fig. 8A ). This indicates that these four complexes represent specific protein-DNA interactions and that their formation correlates with cAMP-regulated G6Pase catalytic subunit conferred by CRE1.
Gel retardation assays were performed in which HepG2 cell nuclear extract was pre-incubated with antisera specific for transcription factors which are known to bind CRE motifs (14, 58) . Schmoll et al. (68) have reported that using nuclear extracts from either human HepG2 or rat hepatoma H4IIE cells, CRE1
only binds a single factor which was identified as CREB. However, as can be seen in Figure 8A , addition of antibodies recognizing CREB resulted in a selective disruption in the formation of only complex 1 with no effect on the formation of complexes 2-4. Concomitant with the disruption of complex 1 a clear supershift was apparent upon addition of the CREB antisera. To identify the factors present in the other three complexes, gel retardation assays were performed in which HepG2 cell nuclear extract was preincubated with antisera specific for different members of the C/EBP transcription factor family (64) . It has been previously shown that members of the C/EBP transcription factor family bind the CRE motif in the phosphoenolpyruvate carboxykinase (PEPCK) gene promoter (60, 62) . Figure 8B shows that addition of antibodies recognizing C/EBPα resulted in a selective disruption in the formation of only complexes 2 and 3 with no effect on the formation of complexes 1 and 4 whereas addition of antibodies recognizing C/EBPβ resulted in a selective disruption in the formation of only complex 4 with no effect on the formation of complexes 1-3. Concomitant with the disruption of complexes 2-4 a clear supershift was apparent upon addition of the C/EBPα and C/EBPβ antisera (Fig. 8B) . Addition of antibodies recognizing C/EBPδ had no effect on complex formation (Fig. 8B) . These results suggests that complex 1 contains CREB, complexes 2 and 3 contain C/EBPα, and complex 4 contains C/EBPβ. Previous studies suggest that C/EBPα is susceptible to proteolysis such that complexes 2 and 3 may represent the binding of full length and truncated C/EBPα, respectively (60).
It is unclear why Schmoll et al. (68) only detected binding of CREB to CRE1 whereas we detect the binding of CREB, C/EBPα and C/EBPβ. However, when a labeled oligonucleotide representing a consensus wild type (WT) CRE sequence was incubated with nuclear extract prepared from HepG2 cells only a single protein-DNA complex was detected (Fig. 8A) . Competition experiments, in which a 100-fold molar excess of unlabeled DNA was included with the labeled probe, showed that the WT consensus CRE oligonucleotide competed effectively for the formation of this protein-DNA complex whereas an unrelated random (RN) oligonucleotide failed to compete with the labeled probe for formation of this complex (Fig.   8A ). This indicates that this complex represents a specific protein-DNA interaction. Addition of antibodies recognizing CREB resulted in a selective disruption in the formation of this complex concomitant with the formation of a clear supershift (Fig. 8A) . Antisera to C/EBPα, C/EBPβ and C/EBPδ had no effect on complex formation (data not shown). The core sequence of the G6Pase catalytic subunit CRE (TTACGTAA) differs from the consensus CRE (TGACGTCA) which may explain this difference in transcription factor binding.
Discussion
We have previously shown that, in pancreatic-clamped, euglycemic conscious dogs, a 5 hr period of hypoinsulinemia leads to a marked increase in hepatic G6Pase catalytic subunit mRNA whereas G6P
transporter mRNA remains unchanged (35) . Although the dog studies described here were initially designed for a different purpose, namely to determine the effect of elevated circulating NEFA levels on glucagon action in vivo, we were able to use the samples already generated to address the question as to what factor is likely to be responsible for the selective induction of G6Pase catalytic subunit gene expression in hypoinsulinemic dogs. We show that glucagon is a prime candidate for this factor. Thus, glucagon selectively stimulated G6Pase catalytic subunit but not G6P transporter gene expression in vivo (Fig. 3 ). This stimulation of G6Pase catalytic subunit gene expression cannot be due to the secondary rise in glucose levels induced by the elevation in glucagon concentration since the resulting glucose level was identical to that in the control, hyperglycemic animals ( Fig. 2) . Moreover, it is unlikely that glucagon alters the abundance of another metabolite/factor that then mediates the induction of G6Pase catalytic subunit gene expression since glucagon can directly stimulate G6Pase catalytic subunit fusion gene expression in HepG2 hepatoma cells (Fig. 4) . Furthermore, cAMP also stimulated endogenous G6Pase catalytic subunit gene expression in HepG2 cells but had no effect on G6P transporter gene expression (Fig. 5 ). This result is consistent with previous results showing that cAMP selectively stimulates G6Pase catalytic subunit, but not G6P transporter, gene expression in rat H4IIE cells and rat primary hepatocytes (35) . Moreover, although Van de Werve and colleagues initially reported that, in HepG2 cells, cAMP stimulated G6P transporter gene expression (40) , more recently they reported that cAMP had no effect (41).
In the substrate-transport model for G6Pase, the translocation of G6P across the ER membrane was identified as a major control point in the G6Pase reaction on the basis of the phenomenon of latency, which is defined as the difference in the rate of G6P hydolysis by intact versus disrupted microsomes (5).
Disruption of microsomes with detergents increases the rate of G6P hydrolysis suggesting that G6P transport is limiting (5). However, Newgard and colleagues have shown, using adenoviral technology, that overexpression of either the G6Pase catalytic subunit (70) or G6P transporter (1) is sufficient to cause an increased rate of hepatic glucose production in primary hepatocyes. These experiments suggest that both the G6Pase catalytic subunit and G6P transporter contribute significantly to the overall rate of the G6Pase reaction. The data presented here and in our previous study (35) suggest that hormones differentially regulate G6Pase catalytic subunit gene expression and G6P transporter gene expression. This then may explain the observations that the degree of latency varies in microsomes prepared from fed or fasted rats (5) and with aging (27) . One caveat with this hypothesis is that it is based on the assumption that G6Pase catalytic subunit and G6P transporter mRNA and protein/activity levels correlate. Studies on gene expression changes during liver regeneration show that this is not necessarily the case. G6Pase catalytic subunit mRNA is induced 30-fold during liver regeneration but there is little (29) or no (81) change in G6Pase catalytic subunit protein or G6Pase enzyme activity. Furthermore, it cannot be assumed that the changes in G6Pase catalytic subunit and G6P transporter mRNA reported in our studies reflect transcriptional changes since many hepatic genes are regulated at the level of mRNA stability (37), including the G6Pase catalytic subunit (48).
Multiple promoter elements are required to mediate the stimulatory effect of cAMP on G6Pase catalytic subunit gene expression in HepG2 cells (73, 75) . However, we show here that the main target for cAMP signaling is the element CRE1, located between -162 and -155 (Fig. 7) . We speculate that other elements in the G6Pase catalytic subunit promoter, such as CRE2, bind accessory factors that act to enhance cAMP signaling through CRE1. Such an arrangement is referred to as a cAMP response unit (CRU) (46, 65) . One exception is an HNF-6 motif located between -110 and -101 that can directly mediate cAMP signaling by a mechanism that involves direct phosphorylation of HNF-6 by PKA (73) . However, cAMP signaling through CRE1 appears to be quantitatively more important than cAMP signaling through the HNF-6 motif (73).
A key question that remains to be addressed is which CRE1 bound factor mediates cAMP signaling? Gel retardation assays show that CRE1 can bind CREB, C/EBPα, and C/EBPβ in vitro (Fig.   8 ). Moreover, studies on the PEPCK promoter, using chimeric GAL4 fusion proteins, show that each of these factors can directly mediate cAMP signaling (79) . The mechanism of cAMP signaling through CREB is well established and involves the direct phosphorylation of CREB by PKA which then leads to binding of the coactivator CBP (14, 58) . In contrast, when bound to the PEPCK promoter, cAMP activates C/EBPα and C/EBPβ through an unknown mechanism that does not involve the direct phosphorylation of these factors by PKA (79) . It is therefore possible that cAMP can activate G6Pase catalytic subunit gene expression through CRE1 regardless of which specific factor is bound. However, it is more likely that the selective binding of each of these factors will be important for different aspects of G6Pase catalytic subunit gene expression. For example, binding of C/EBPβ, but not C/EBPα or CREB, to the CRE in the PEPCK promoter is required for the maximal glucocorticoid-stimulated expression of that gene (80) . Studies of mice expressing dominant negative CREB (34) and studies in which the genes encoding C/EBPα (78), and C/EBPβ (7) have been selectively deleted support the involvement of all of all of these factors in the regulation of G6Pase catalytic subunit gene expression. However, the changes in G6Pase catalytic subunit gene expression observed in these animals could be indirect. In addition, C/EBPα and C/EBPβ may bind to other elements in the G6Pase catalytic subunit promoter other than CRE1 (4, 43).
Commerford et al. (13) have recently shown that high fat diets do not affect G6P transporter gene expression in rats. However, the lack of a stimulatory effect of fatty acids and glycerol on G6Pase catalytic subunit gene expression in conscious dogs in vivo (Fig. 3) was surprising because feeding rats high fat diets (13), infusing conscious rats with a triglyceride emulsion (51) or treating primary rat hepatocytes with either short chain (49) or long chain (11) fatty acids, all elevate rat G6Pase catalytic subunit gene expression. Similarly, glycerol increases G6Pase catalytic subunit mRNA levels in rat primary hepatocytes (48) . The reason for this lack of stimulation of G6Pase catalytic subunit gene expression by NEFA in conscious dogs is unclear. The concentration of NEFA achieved in our study (~1500 µmol/L; Fig. 2E ) is similar to that reported by Rossetti and colleagues in studies involving the infusion of conscious rats with a triglyceride emulsion (51) . However, Rossetti and colleagues used Liposyn (Abbott) rather than Intralipid (Baxter) as the source of fatty acids; the fatty acid composition of these products are not identical. This may be significant since the regulation of G6Pase catalytic subunit gene expression by fatty acids is complex. Thus, although short and long chain fatty acids stimulate G6Pase catalytic subunit gene expression, polyunsaturated fatty acids actually suppress expression of the gene (63) . Perhaps more significant, in the study by Rossetti and colleagues (51) the animals were mildly hyperinsulinemic and glucagon was not replaced following somatostatin administration. It is therefore possible that basal G6Pase catalytic subunit gene expression was reduced relative to the level seen in our dogs in which insulin and glucagon were both at basal levels. Such a reduction in basal G6Pase catalytic subunit gene expression might make a stimulatory effect of fatty acids more apparent.
Another possible explanation for the lack of fatty acid-stimulated G6Pase catalytic subunit gene expression in conscious dogs in vivo is that this gene is regulated differently in dogs and rats.
Interestingly, we have previously reported that, in conscious dogs in vivo, glucose also fails to stimulate G6Pase catalytic subunit gene expression (35) . In contrast, in conscious rats (50, 52) , primary rat hepatocytes (3, 11, 48) and rat FAO hepatoma cells (3, 38) glucose stimulates rat G6Pase catalytic subunit gene expression. We propose to explore this potential differential regulation of rat and dog G6Pase catalytic subunit gene expression in future experiments that will involve the cloning of the dog G6Pase catalytic subunit gene promoter. The comparative analysis of the rat and dog promoters in both rat and dog primary hepatocytes will reveal whether there is an inherent difference in NEFA and glucose signaling between these species or a specific difference in the regulation of dog G6Pase catalytic subunit gene expression. Such primary hepatocyte studies will also be critical for confirming the results of our analysis of PKA-stimulated G6Pase catalytic subunit fusion gene transcription in HepG2 cells. This is an important issue since HepG2 cells (36) and hepatoma cells in general (31) differ from normal liver cells in several aspects, including reduced gluconeogenic capacity, and therefore may be lacking other key transcription factors or proteins important for understanding the regulation of this gene.
In summary, this manuscript demonstrates that glucagon and its second messenger cAMP differentially regulate the hepatic expression of the genes encoding the G6Pase catalytic subunit and the G6P transporter in vivo and in situ. In contrast, insulin suppresses the expression of both genes, though the magnitude of the effect of insulin is much greater on G6Pase catalytic subunit gene expression (35) .
Interestingly, there have been two recent reports that described a differential regulation of G6Pase catalytic subunit and the G6P transporter gene expression in the liver of mice bearing Ehrlich ascites tumor cells (23) and in the clear cell type of human renal cell carcinoma (67) , although the mechanisms responsible for this differential regulation were not elucidated. Following pancreatic clamping, as shown in Fig. 1 , liver samples were removed and total RNA was isolated. G6Pase catalytic subunit mRNA, G6P transporter mRNA and cyclophilin A mRNA were then quantified, as described in Methods, using the ribonuclease protection assay. The data is expressed as the ratio of G6Pase catalytic subunit mRNA (Panel A) or G6P transporter mRNA (Panel B) to cyclophilin A mRNA and the results represent the mean ratio + S.E.M. in RNA preparations isolated from three to four independent animals in each experimental protocol, with all samples assayed in duplicate. *P<0.05 vs.
control. HG, hyperglycemia; GGN, glucagon; NEFA, non-esterified fatty acid. 
